

Non-clinical study and IND approval of GI-108, a metabolic immune anti-cancer drug



ONCOLOGY	Non-Clinical
Product Type	Biologics-Protein (Antibody)
Indication	Solid tumors (CD73 high-expressing tumors, ICI-refractory/resistant tumors)
Target	Anti-CD73-IgG4 Fc-IL-2v3
MoA(Mechanism of Action)	<ul style="list-style-type: none"> - Anti-CD73 : Reinvigoration of anti-cancer effect of tumor-infiltrating immune cells via tumor targeting and suppression of adenosine production - IL-2 variants (IL-2v3): Synergistic effect on the proliferation and activation of anti-cancer immune cells such as CD8+ T cells/NK cells with minimal effect of regulatory T cells
Competitiveness	<ul style="list-style-type: none"> - First-in-class metabolic immune anti-cancer drug with bispecific fusion of IL-2 and anti-CD73 antibody - High anti-cancer efficacy and low toxicity by optimization of IL-2 mutants, tumor targeting IL-2 action and superior anti-CD73 activity - Potentially high anti-cancer efficacy in anti-cancer drugs (chemical drugs or immune checkpoint inhibitors)-refractory or -resistant patients - Potentially synergistic anti-cancer efficacy via combination administration with standard treatments or blockbuster immune checkpoint inhibitors
Development Stage	Non-Clinical
Route of Administration	Intravenous (i.v) administration, once every 2 or 3 weeks